A randomised, double-blind, placebo-controlled, parallel group trial evaluating safety, tolerability, pharmacodynamics and pharmacokinetics of BI 1291583 one tablet once daily over 12 weeks versus placebo in adult patients with cystic fibrosis bronchiectasis (ClairaflyTM) (Böhringer_1397- 0013)
The primary objective of the study is to investigate safety and tolerability of 5 mg BI 1291583 in patients with CFB following oral daily administration over 12 weeks.
Study details
Study-ID: NCT05865886, 2022-502835-21-00
Study-ID: NCT05865886, 2022-502835-21-00
DZL Disease Area: CFBE
DZL Disease Area: CFBE
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center, DZL on steering board
DZL Role: DZL recruiting center, DZL on steering board
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: BIH / Charité - Associated Partner
DZL Participating Sites: BIH / Charité - Associated Partner
Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu.
Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.
